Gamma-glutamyltransferase—friend or foe within?

Liver International

Volumn 36, Issue 12, 2016, Pages 1723-1734

  Kunutsor, Setor K ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

dementia; diabetes; fracture; gamma glutamyltransferase; mortality; vascular disease

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CLINICAL OUTCOME; DEMENTIA; DISEASE MARKER; ENZYME ACTIVITY; FRACTURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC ASSOCIATION; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUDDEN CARDIAC DEATH; BLOOD; DIABETES MELLITUS; ENZYMOLOGY; LIVER; LIVER DISEASE; MORTALITY; RISK FACTOR; VASCULAR DISEASE;

BIOMARKERS; DEMENTIA; DIABETES MELLITUS; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; LIVER DISEASES; MORTALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VASCULAR DISEASES;

EID: 84992364874     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13221     Document Type: Review

References (129)

1. Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol. 2010;13:36–41.
2. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov. 2007;6:904–916.
3. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001;38:263–355.
4. Paolicchi A, Emdin M, Passino C, et al. Beta-lipoprotein- and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis. 2006;186:80–85.
5. Sacchetti L, Castaldo G, Fortunato G, Salvatore F. Improved procedure for measuring gamma-glutamyltransferase isoenzymes in serum. Clin Chem. 1988;34:419–422.
6. Franzini M, Bramanti E, Ottaviano V, et al. A high performance gel filtration chromatography method for gamma-glutamyltransferase fraction analysis. Anal Biochem. 2008;374:1–6.
7. Franzini M, Paolicchi A, Fornaciari I, et al. Cardiovascular risk factors and gamma-glutamyltransferase fractions in healthy individuals. Clin Chem Lab Med. 2010;48:713–717.
8. Collins JE, Mungall AJ, Badcock KL, Fay JM, Dunham I. The organization of the gamma-glutamyl transferase genes and other low copy repeats in human chromosome 22q11. Genome Res. 1997;7:522–531.
9. Figlewicz DA, Delattre O, Guellaen G, et al. Mapping of human gamma-glutamyl transpeptidase genes on chromosome 22 and other human autosomes. Genomics. 1993;17:299–305.
10. Lieberman MW, Barrios R, Carter BZ, et al. Gamma-Glutamyl transpeptidase. What does the organization and expression of a multipromoter gene tell us about its functions? Am J Pathol. 1995;147:1175–1185.
11. Middelberg RP, Benyamin B, de Moor MH, et al. Loci affecting gamma-glutamyl transferase in adults and adolescents show age x SNP interaction and cardiometabolic disease associations. Hum Mol Genet. 2012;21:446–455.
12. Bathum L, Petersen HC, Rosholm JU, Hyltoft Petersen P, Vaupel J, Christensen K. Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study. Clin Chem. 2001;47:81–87.
13. Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin Chem. 2002;48:1426–1431.
14. Rahmioglu N, Andrew T, Cherkas L, et al. Epidemiology and genetic epidemiology of the liver function test proteins. PLoS One. 2009;4:e4435.
15. van Beek JH, de Moor MH, de Geus EJ, et al. The genetic architecture of liver enzyme levels: GGT, ALT and AST. Behav Genet. 2013;43:329–339.
16. Meister A. The gamma-glutamyl cycle. Diseases associated with specific enzyme deficiencies. Ann Intern Med. 1974;81:247–253.
17. Raulf M, Stuning M, Konig W. Metabolism of leukotrienes by L-gamma-glutamyl-transpeptidase and dipeptidase from human polymorphonuclear granulocytes. Immunology. 1985;55:135–147.
18. Schiele F, Guilmin AM, Detienne H, Siest G. Gamma-glutamyltransferase activity in plasma: statistical distributions, individual variations, and reference intervals. Clin Chem. 1977;23:1023–1028.
19. Gunter EW, Lewis BG, Koncikowski SM. Laboratory procedures used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Environmental Health, National Center for Health Statistics; 1996.
20. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163 944 Austrian adults. Circulation. 2005;112:2130–2137.
21. Sano J, Kawada H, Yamaguchi N, Kawakita M, Kobayashi K. Effects of phenytoin on serum gamma-glutamyl transpeptidase activity. Epilepsia. 1981;22:331–338.
22. Nilssen O, Forde OH, Brenn T. The Tromso Study. Distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol. 1990;132:318–326.
23. Nilssen O, Forde OH. Seven-year longitudinal population study of change in gamma-glutamyltransferase: the Tromso Study. Am J Epidemiol. 1994;139:787–792.
24. Lee DH, Steffen LM, Jacobs DR Jr. Association between serum gamma-glutamyltransferase and dietary factors: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Clin Nutr. 2004;79:600–605.
25. Arnesen E, Huseby NE, Brenn T, Try K. The Tromso Heart Study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. Scand J Clin Lab Invest. 1986;46:63–70.
26. Salvaggio A, Periti M, Miano L, Tavanelli M, Marzorati D. Body mass index and liver enzyme activity in serum. Clin Chem. 1991;37:720–723.
27. Ikai E, Honda R, Yamada Y. Serum gamma-glutamyl transpeptidase level and blood pressure in nondrinkers: a possible pathogenetic role of fatty liver in obesity-related hypertension. J Hum Hypertens. 1994;8:95–100.
28. Conen D, Vollenweider P, Rousson V, et al. Use of a mendelian randomization approach to assess the causal relation of gamma-glutamyltransferase with blood pressure and serum insulin levels. Am J Epidemiol. 2010;172:1431–1441.
29. Fall T, Hagg S, Magi R, et al. The role of adiposity in cardiometabolic traits: a mendelian randomization analysis. PLoS Med. 2013;10:e1001474.
30. Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. Curr Diab Rep. 2008;8:25–30.
31. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202–1219.
32. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. Diabetes. 2001;50:1844–1850.
33. Fan JG, Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease: Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int. 2007;6:572–578.
34. Jin HB, Gu ZY, Yu CH, Li YM. Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. Hepatobiliary Pancreat Dis Int. 2005;4:389–392.
35. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–117.
36. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.
37. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
38. de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(Suppl 1):S104–S112.
39. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231.
40. Marchesini G, Moscatiello S, di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93(11 Suppl 1):S74–S80.
41. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
42. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:863–869.
43. Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S. Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Kidney Int. 2011;79:228–233.
44. Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep. 2008;10:73–80.
45. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–967.
46. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.
47. Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ. 2014;349:g4596.
48. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–1292.
49. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–1362.
50. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121.
51. Valbusa F, Bonapace S, Grillo C, et al. Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine (Baltimore). 2016;95:e2760.
52. Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61:1246–1267.
53. Mantovani A, Rigamonti A, Bonapace S, et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring. Diabetes Care. 2016;39:1416–1423.
54. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656–665.
55. Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64:638–652.
56. Seo SW, Gottesman RF, Clark JM, et al. Nonalcoholic fatty liver disease is associated with cognitive function in adults. Neurology. 2016;86:1136–1142.
57. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol. 2007;27:2729–2735.
58. Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis. 2014;236:7–17.
59. Du G, Song Z, Zhang Q. Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med. 2013;57:31–37.
60. Long Y, Zeng F, Shi J, Tian H, Chen T. Gamma-glutamyltransferase predicts increased risk of mortality: a systematic review and meta-analysis of prospective observational studies. Free Radic Res. 2014;48:716–728.
61. Zhang XW, Li M, Hou WS, Li K, Zhou JR, Tang ZY. Association between gamma-glutamyltransferase level and risk of stroke: a systematic review and meta-analysis of prospective studies. J Stroke Cerebrovasc Dis. 2015;24:2816–2823.
62. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology. 2010;52:1156–1161.
63. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341–1350.
64. Wannamethee SG, Lennon L, Shaper AG. The value of gamma-glutamyltransferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis. 2008;201:168–175.
65. Lee DS, Evans JC, Robins SJ, et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2007;27:127–133.
66. Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP. Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis. 2014;238:356–364.
67. Emdin M, Pompella A, Paolicchi A. Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation. 2005;112:2078–2080.
68. Franzini M, Corti A, Martinelli B, et al. Gamma-glutamyltransferase activity in human atherosclerotic plaques–biochemical similarities with the circulating enzyme. Atherosclerosis. 2009;202:119–127.
69. Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38:535–539.
70. Anderson ME, Allison RD, Meister A. Interconversion of leukotrienes catalyzed by purified gamma-glutamyl transpeptidase: concomitant formation of leukotriene D4 and gamma-glutamyl amino acids. Proc Natl Acad Sci USA. 1982;79:1088–1091.
71. Emdin M, Passino C, Donato L, Paolicchi A, Pompella A. Serum gamma-glutamyltransferase as a risk factor of ischemic stroke might be independent of alcohol consumption. Stroke. 2002;33:1163–1164.
72. Paolicchi A, Emdin M, Ghliozeni E, et al. Human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation. 2004;109:1440.
73. Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:629–650.
74. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589–600.
75. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79–104.
76. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22.
77. Yuan X, Waterworth D, Perry JR, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet. 2008;83:520–528.
78. Kamatani Y, Matsuda K, Okada Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet. 2010;42:210–215.
79. Chambers JC, Zhang W, Sehmi J, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet. 2011;43:1131–1138.
80. Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino RB Sr, Vasan RS. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol. 2010;30:1855–1860.
81. Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol. 2012;32:830–835.
82. Wang Y, Tuomilehto J, Jousilahti P, et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart. 2013;99:163–167.
83. Kunutsor SK, Khan H, Laukkanen JA. Gamma-Glutamyltransferase and risk of sudden cardiac death in middle-aged finnish men: a new prospective cohort study. J Am Heart Assoc. 2016;5:e002858.
84. Macmahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–774.
85. Kunutsor SK, Laukkanen JA, Bluemke DA, Butler J, Khan H. Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: prospective study and pooled analysis of published evidence. Eur J Prev Cardiol. 2016;23:1354–1362.
86. Targher G, Bertolini L, Rodella S, et al. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring). 2008;16:1394–1399.
87. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52:59–69.
88. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109(21 Suppl 1):II27–II33.
89. Ha MH, Lee DH, Jacobs DR. Association between serum concentrations of persistent organic pollutants and self-reported cardiovascular disease prevalence: results from the National Health and Nutrition Examination Survey, 1999–2002. Environ Health Perspect. 2007;115:1204–1209.
90. Alonso A, Misialek JR, Amiin MA, et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart. 2014;100:1511–1516.
91. Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res. 2009;19:319–326.
92. Perry IJ, Wannamethee SG, Shaper AG. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care. 1998;21:732–737.
93. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–750.
94. Kunutsor SK, Abbasi A, Adler AI. Gamma-glutamyl transferase and risk of type II diabetes: an updated systematic review and dose-response meta-analysis. Ann Epidemiol. 2014;24:809–816.
95. Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936–944.
96. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24:816–823.
97. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S53–S55.
98. Raynor LA, Pankow JS, Duncan BB, et al. Novel risk factors and the prediction of type 2 diabetes in the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2013;36:70–76.
99. Marques-Vidal P, Schmid R, Bochud M, et al. Adipocytokines, hepatic and inflammatory biomarkers and incidence of type 2 diabetes. the CoLaus study. PLoS One. 2012;7:e51768.
100. Liu CF, Zhou WN, Fang NY. Gamma-glutamyltransferase levels and risk of metabolic syndrome: a meta-analysis of prospective cohort studies. Int J Clin Pract. 2012;66:692–698.
101. Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose-response meta-analysis. Int J Clin Pract. 2015;69:136–144.
102. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003;92:10J–17J.
103. Loomba R, Rao F, Zhang L, et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology. 2010;139:836–845, 45 e1.
104. Liu CF, Gu YT, Wang HY, Fang NY. Gamma-glutamyltransferase level and risk of hypertension: a systematic review and meta-analysis. PLoS ONE. 2012;7:e48878.
105. Kunutsor SK, Apekey TA, Cheung BM. Gamma-glutamyltransferase and risk of hypertension: a systematic review and dose-response meta-analysis of prospective evidence. J Hypertens. 2015;33:2373–2381.
106. Zhou MS, Wang A, Yu H. Link between insulin resistance and hypertension: what is the evidence from evolutionary biology? Diabetol Metab Syndr. 2014;6:12.
107. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens. 1995;9:101–105.
108. Kunutsor SK, Apekey TA, Hemelrijck MV, Calori G, Perseghin G. Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis. Int J Cancer. 2014;136:1162–1170.
109. Preyer O, Johansen D, Holly J, et al. Gamma-glutamyltransferase and breast cancer risk beyond alcohol consumption and other life style factors – a pooled cohort analysis. PLoS One. 2016;11:e0149122.
110. Pompella A, Corti A, Paolicchi A, Giommarelli C, Zunino F. Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr Opin Pharmacol. 2007;7:360–366.
111. Franzini M, Corti A, Lorenzini E, et al. Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells. Eur J Cancer. 2006;42:2623–2630.
112. Hanigan MH, Gallagher BC, Townsend DM, Gabarra V. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis. 1999;20:553–559.
113. Pompella A, de Tata V, Paolicchi A, Zunino F. Expression of gamma-glutamyltransferase in cancer cells and its significance in drug resistance. Biochem Pharmacol. 2006;71:231–238.
114. Ryu S, Chang Y, Kim DI, Kim WS, Suh BS. Gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin Chem. 2007;53:71–77.
115. Schnackenberg CG, Welch WJ, Wilcox CS. TP receptor-mediated vasoconstriction in microperfused afferent arterioles: roles of O(2)(-) and NO. Am J Physiol Renal Physiol. 2000;279:F302–F308.
116. Zou AP, Li N, Cowley AW Jr. Production and actions of superoxide in the renal medulla. Hypertension. 2001;37(2 Pt 2):547–553.
117. Niida S, Kawahara M, Ishizuka Y, et al. Gamma-glutamyltranspeptidase stimulates receptor activator of nuclear factor-kappaB ligand expression independent of its enzymatic activity and serves as a pathological bone-resorbing factor. J Biol Chem. 2004;279:5752–5756.
118. Hiramatsu K, Asaba Y, Takeshita S, et al. Overexpression of gamma-glutamyltransferase in transgenic mice accelerates bone resorption and causes osteoporosis. Endocrinology. 2007;148:2708–2715.
119. Lee NK, Choi YG, Baik JY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood. 2005;106:852–859.
120. Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y. Oxidative stress in bone remodelling and disease. Trends Mol Med. 2009;15:468–477.
121. Kunutsor SK, Laukkanen JA. Gamma glutamyltransferase and risk of future dementia in middle-aged to older Finnish men: a new prospective cohort study. Alzheimers Dement. 2016; doi:10.1016/j.jalz.2016.03.003. [Epub ahead of print].
122. Zafrilla P, Mulero J, Xandri JM, Santo E, Caravaca G, Morillas JM. Oxidative stress in Alzheimer patients in different stages of the disease. Curr Med Chem. 2006;13:1075–1083.
123. Gackowski D, Rozalski R, Siomek A, et al. Oxidative stress and oxidative DNA damage is characteristic for mixed Alzheimer disease/vascular dementia. J Neurol Sci. 2008;266:57–62.
124. McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126:479–497.
125. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4:147–152.
126. Mannan HR, Stevenson CE, Peeters A, McNeil JJ. A new set of risk equations for predicting long term risk of all-cause mortality using cardiovascular risk factors. Prev Med. 2013;56:41–45.
127. Kunutsor S, Apekey TA, Seddoh D, Walley J. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol. 2014;43:187–201.
128. Rusu E, Jinga M, Enache G, et al. Effects of lifestyle changes including specific dietary intervention and physical activity in the management of patients with chronic hepatitis C–a randomized trial. Nutr J. 2013;12:119.
129. Suzuki A, Lindor K, St Saver J, et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol. 2005;43:1060–1066.